AdCLD-CoV19-1 OMI / Cellid - LARVOL DELTA

Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P3 | N=4000 | Active, not recruiting | Sponsor: Cellid Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Nov 2024 ➔ Mar 2025

Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P3 | N=4000 | Recruiting | Sponsor: Cellid Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: May 2025 ➔ Oct 2025 | Trial primary completion date: May 2024 ➔ Nov 2024

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine (clinicaltrials.gov) - P1/2 | N=320 | Completed | Sponsor: Cellid Co., Ltd. | Active, not recruiting ➔ Completed | Phase classification: P2 ➔ P1/2

Phase classification • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P3 | N=4000 | Not yet recruiting | Sponsor: Cellid Co., Ltd.

New P3 trial • Infectious Disease • Novel Coronavirus Disease

Development of broadly protective COVID-19 vaccine against up-to-date variants based on adenovirus type 5/35 vector platform. (P664) (IMMUNOLOGY 2023) - "We previously developed AdCLD-CoV19-1 OMI, an Ad5/35 platform based non-replicating recombinant adenoviral vector that encodes the spike protein of BA.1, and currently performing clinical studies...We further investigate combinations of next-generation multivalent vaccines to confer broad protection against new subvariants. Based on the results of preclinical studies, clinical trials of the polyvalent vaccines will be conducted."

Late-breaking abstract • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine (clinicaltrials.gov) - P2 | N=320 | Active, not recruiting | Sponsor: Cellid Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine (clinicaltrials.gov) - P2 | N=320 | Recruiting | Sponsor: Cellid Co., Ltd. | Active, not recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine (clinicaltrials.gov) - P2 | N=320 | Active, not recruiting | Sponsor: Cellid Co., Ltd.

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases